.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Moodys
Covington
Johnson and Johnson
Novartis
Colorcon
Deloitte
US Department of Justice
Fuji

Generated: December 14, 2017

DrugPatentWatch Database Preview

US Patents With Foreign Priority to Denmark Patent: 1470/96

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Novo Nordisk IncSAXENDAliraglutide recombinantSOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes► Subscribe► Subscribe► SubscribeYY
Novo Nordisk IncVICTOZAliraglutide recombinantSOLUTION;SUBCUTANEOUS022341-001Jan 25, 2010RXYesYes► Subscribe► Subscribe► SubscribeYY
Novo Nordisk IncXULTOPHY 100/3.6insulin degludec; liraglutideSOLUTION;SUBCUTANEOUS208583-001Nov 21, 2016RXYesYes► Subscribe► Subscribe► SubscribeY
Novo Nordisk IncSAXENDAliraglutide recombinantSOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes► Subscribe► Subscribe► SubscribeYYMETHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
Novo Nordisk IncVICTOZAliraglutide recombinantSOLUTION;SUBCUTANEOUS022341-001Jan 25, 2010RXYesYes► Subscribe► Subscribe► SubscribeYYA METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
Novo Nordisk IncXULTOPHY 100/3.6insulin degludec; liraglutideSOLUTION;SUBCUTANEOUS208583-001Nov 21, 2016RXYesYes► Subscribe► Subscribe► SubscribeYY
Novo Nordisk IncSAXENDAliraglutide recombinantSOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes► Subscribe► Subscribe► SubscribeYYMETHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
Novo Nordisk IncVICTOZAliraglutide recombinantSOLUTION;SUBCUTANEOUS022341-001Jan 25, 2010RXYesYes► Subscribe► Subscribe► SubscribeYYA METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
Novo Nordisk IncXULTOPHY 100/3.6insulin degludec; liraglutideSOLUTION;SUBCUTANEOUS208583-001Nov 21, 2016RXYesYes► Subscribe► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Table 'thinkbio_newdpw.patent_gazette' doesn't exist